|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CENPW |
Gene summary for CENPW |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CENPW | Gene ID | 387103 |
| Gene name | centromere protein W | |
| Gene Alias | C6orf173 | |
| Cytomap | 6q22.32 | |
| Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | Q5EE01 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 387103 | CENPW | Tumor | Human | Cervix | CC | 5.15e-72 | 1.18e+00 | 0.1241 |
| 387103 | CENPW | sample1 | Human | Cervix | CC | 2.11e-13 | 7.85e-01 | 0.0959 |
| 387103 | CENPW | sample3 | Human | Cervix | CC | 9.70e-62 | 1.04e+00 | 0.1387 |
| 387103 | CENPW | L1 | Human | Cervix | CC | 2.06e-09 | 6.13e-01 | 0.0802 |
| 387103 | CENPW | T1 | Human | Cervix | CC | 2.85e-11 | 5.65e-01 | 0.0918 |
| 387103 | CENPW | T3 | Human | Cervix | CC | 6.66e-73 | 1.04e+00 | 0.1389 |
| 387103 | CENPW | LZE2T | Human | Esophagus | ESCC | 4.90e-12 | 1.62e+00 | 0.082 |
| 387103 | CENPW | LZE7T | Human | Esophagus | ESCC | 2.55e-06 | 7.43e-01 | 0.0667 |
| 387103 | CENPW | LZE8T | Human | Esophagus | ESCC | 1.00e-03 | 3.46e-01 | 0.067 |
| 387103 | CENPW | LZE20T | Human | Esophagus | ESCC | 3.91e-10 | 7.50e-01 | 0.0662 |
| 387103 | CENPW | LZE24T | Human | Esophagus | ESCC | 1.30e-02 | 4.39e-01 | 0.0596 |
| 387103 | CENPW | LZE6T | Human | Esophagus | ESCC | 3.59e-07 | 6.51e-01 | 0.0845 |
| 387103 | CENPW | P1T-E | Human | Esophagus | ESCC | 3.45e-07 | 5.35e-01 | 0.0875 |
| 387103 | CENPW | P2T-E | Human | Esophagus | ESCC | 3.45e-31 | 9.21e-01 | 0.1177 |
| 387103 | CENPW | P4T-E | Human | Esophagus | ESCC | 1.63e-31 | 1.35e+00 | 0.1323 |
| 387103 | CENPW | P5T-E | Human | Esophagus | ESCC | 3.36e-31 | 7.90e-01 | 0.1327 |
| 387103 | CENPW | P8T-E | Human | Esophagus | ESCC | 4.92e-03 | 2.22e-01 | 0.0889 |
| 387103 | CENPW | P9T-E | Human | Esophagus | ESCC | 8.16e-27 | 1.14e+00 | 0.1131 |
| 387103 | CENPW | P10T-E | Human | Esophagus | ESCC | 4.49e-13 | 4.65e-01 | 0.116 |
| 387103 | CENPW | P12T-E | Human | Esophagus | ESCC | 3.82e-11 | 4.12e-01 | 0.1122 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00063257 | Cervix | CC | chromatin organization | 78/2311 | 409/18723 | 5.40e-05 | 8.02e-04 | 78 |
| GO:00063381 | Cervix | CC | chromatin remodeling | 45/2311 | 255/18723 | 8.33e-03 | 4.30e-02 | 45 |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:000632517 | Esophagus | ESCC | chromatin organization | 240/8552 | 409/18723 | 6.52e-08 | 1.14e-06 | 240 |
| GO:00513831 | Esophagus | ESCC | kinetochore organization | 21/8552 | 23/18723 | 5.69e-06 | 5.90e-05 | 21 |
| GO:00345081 | Esophagus | ESCC | centromere complex assembly | 25/8552 | 30/18723 | 2.45e-05 | 2.09e-04 | 25 |
| GO:00513821 | Esophagus | ESCC | kinetochore assembly | 16/8552 | 18/18723 | 1.78e-04 | 1.15e-03 | 16 |
| GO:0031055 | Esophagus | ESCC | chromatin remodeling at centromere | 9/8552 | 10/18723 | 5.09e-03 | 1.92e-02 | 9 |
| GO:0043486 | Esophagus | ESCC | histone exchange | 16/8552 | 22/18723 | 9.46e-03 | 3.28e-02 | 16 |
| GO:0007059 | Liver | HCC | chromosome segregation | 197/7958 | 346/18723 | 3.57e-08 | 7.87e-07 | 197 |
| GO:000632511 | Liver | HCC | chromatin organization | 206/7958 | 409/18723 | 7.23e-04 | 4.41e-03 | 206 |
| GO:00070592 | Oral cavity | OSCC | chromosome segregation | 206/7305 | 346/18723 | 5.82e-15 | 3.76e-13 | 206 |
| GO:0051383 | Oral cavity | OSCC | kinetochore organization | 18/7305 | 23/18723 | 1.47e-04 | 1.04e-03 | 18 |
| GO:0034508 | Oral cavity | OSCC | centromere complex assembly | 21/7305 | 30/18723 | 5.75e-04 | 3.30e-03 | 21 |
| GO:0051382 | Oral cavity | OSCC | kinetochore assembly | 14/7305 | 18/18723 | 9.51e-04 | 4.96e-03 | 14 |
| GO:000632510 | Oral cavity | OSCC | chromatin organization | 190/7305 | 409/18723 | 1.17e-03 | 5.97e-03 | 190 |
| GO:00070591 | Oral cavity | LP | chromosome segregation | 117/4623 | 346/18723 | 7.61e-05 | 9.91e-04 | 117 |
| GO:000705912 | Skin | cSCC | chromosome segregation | 161/4864 | 346/18723 | 8.34e-17 | 8.57e-15 | 161 |
| GO:000632519 | Skin | cSCC | chromatin organization | 147/4864 | 409/18723 | 4.41e-06 | 6.52e-05 | 147 |
| GO:000633812 | Skin | cSCC | chromatin remodeling | 94/4864 | 255/18723 | 7.58e-05 | 7.26e-04 | 94 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CENPW | SNV | Missense_Mutation | rs745347945 | c.203N>A | p.Arg68Gln | p.R68Q | Q5EE01 | protein_coding | deleterious(0.03) | probably_damaging(0.99) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CENPW | SNV | Missense_Mutation | novel | c.302N>T | p.Ser101Ile | p.S101I | Q5EE01 | protein_coding | deleterious(0) | possibly_damaging(0.571) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| CENPW | SNV | Missense_Mutation | novel | c.173T>A | p.Val58Asp | p.V58D | Q5EE01 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-AG-A014-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| CENPW | SNV | Missense_Mutation | rs767524679 | c.277G>A | p.Ala93Thr | p.A93T | Q5EE01 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CENPW | SNV | Missense_Mutation | novel | c.55C>A | p.Arg19Ser | p.R19S | Q5EE01 | protein_coding | deleterious(0) | possibly_damaging(0.839) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| CENPW | SNV | Missense_Mutation | rs767524679 | c.277N>A | p.Ala93Thr | p.A93T | Q5EE01 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CENPW | SNV | Missense_Mutation | novel | c.179N>C | p.Leu60Pro | p.L60P | Q5EE01 | protein_coding | deleterious(0.03) | benign(0.074) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CENPW | SNV | Missense_Mutation | c.36G>C | p.Gln12His | p.Q12H | Q5EE01 | protein_coding | tolerated_low_confidence(0.54) | benign(0.41) | TCGA-66-2759-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | carboplatin | CR | |
| CENPW | SNV | Missense_Mutation | rs746698752 | c.233N>T | p.Cys78Phe | p.C78F | Q5EE01 | protein_coding | tolerated(1) | possibly_damaging(0.52) | TCGA-NC-A5HH-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| CENPW | SNV | Missense_Mutation | novel | c.135C>G | p.Phe45Leu | p.F45L | Q5EE01 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-BB-4223-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |